Search Bar & Filters
Found 216 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, tolerability, and pharmacodynamics of 4D-310, a gene therapy, in adults with Fabry Disease who have heart involvement. This open-label, dose-escalation trial includes adult males and females aged 18 to 65 years and aims to understand how the treatment works after a single intravenous dose. Fabry Disease is a condition that affects multiple organs, including the heart, and requires new treatment approaches. Participants receive one single intravenous administration of 4D-310 at different dose levels as part of the study. The trial includes several dose groups, with some dose levels no longer enrolling. The study is conducted across multiple centers and is designed to carefully monitor responses to the gene therapy over time. During the study, participants will be regularly assessed for safety by tracking any adverse events for one year following treatment. Researchers will also monitor how the body responds to the therapy through various evaluations. The total participation time includes screening, treatment, and follow-up visits to ensure thorough observation of treatment effects and safety.
Actively Recruiting
Researchers are investigating a new imaging method for soft tissue sarcoma STS and other solid tumors that express a protein called PDGFR alpha, which could be targeted for treatment. This phase 1 trial studies a special antibody called olaratumab labeled with a radioactive form of zirconium-89 89Zr-olaratumab or 89Zr-TLX300-CDx to see how well it targets tumors and its safety in patients with these PDGFR alpha-positive cancers. Participants will receive a single injection of 89Zr-TLX300-CDx and undergo whole-body imaging at specific times after the injection. The study includes three parts, each with a slightly different imaging schedule and optional blood tests to track the antibodys behavior in the body. Imaging occurs at intervals such as 4 hours, 24 hours, 4 days, 6 days, and 7 days post-injection, depending on the study part. During the trial, participants will have imaging scans, blood samples collected for pharmacokinetic analysis, and safety monitoring. Researchers will evaluate how the antibody is distributed in the body, radiation exposure, and its safety up to 30 days after injection. The results aim to support future development of olaratumab as a radiopharmaceutical for treating certain cancers. The total study duration varies by participant depending on the imaging schedule.
Actively Recruiting
Researchers are investigating new treatments for people with high-risk non-muscle invasive bladder cancer HR NMIBC, a type of bladder cancer that affects the inner lining and has not spread to the muscle. This condition includes carcinoma in situ CIS, a flat cancer limited to the bladders surface. The study aims to find out if adding intismeran autogene to the standard Bacillus Calmette-Guerin BCG treatment can help patients live longer without their cancer growing, spreading, or returning. Participants receive either intismeran autogene combined with BCG or BCG alone. Intismeran autogene is given as a 1 mg intramuscular injection every 3 weeks for nine doses. BCG is administered as a 50 mg intravesicular instillation once weekly for 6 weeks initially, then during weeks 13-15, 25-27, 49-51, and 73-75. Some participants receive only intismeran autogene. The study follows these treatments in separate groups to compare outcomes. During the study, participants undergo assessments over up to approximately five years to measure event-free survival, recurrence-free survival, disease-specific survival, overall survival, and other health outcomes. Researchers track cancer response, monitor adverse events, and evaluate how long participants remain cancer-free. Regular visits and tests help monitor safety and treatment effects throughout the study period.
Actively Recruiting
Researchers are exploring a new treatment for chronic myeloid leukemia CML, a type of blood cancer. The study aims to evaluate the safety and tolerability of different doses of MK-4208 Tern-701 and to identify the highest dose that participants can tolerate and that may be effective in treating CML. This trial is being conducted in phases 1 and 2 to gather important information about MK-4208s use in this disease. Participants will receive MK-4208 orally at various doses ranging from 160 mg to 500 mg, taken once or twice daily depending on the study part. The study includes multiple groups that receive different doses to compare safety and tolerability. Treatment duration and dosing schedules may vary across the study parts, with careful monitoring of participants during the intervention. Throughout the study, participants will undergo regular assessments including monitoring for dose-limiting toxicities, adverse events, and serious side effects up to three years. Researchers will also track hematologic and molecular responses to the treatment and measure drug levels in the blood over time. Safety, tolerability, and efficacy data will be collected to better understand the potential role of MK-4208 in treating CML, with the study expected to last until 2030 for complete follow-up.
Actively Recruiting
Researchers are investigating new medicines for children and young people up to 25 years old with relapsed or refractory B-cell non-Hodgkin Lymphoma B-NHL, a type of cancer affecting lymph nodes and organs like the liver or spleen. This international adaptive trial aims to find safer and more effective treatments, focusing on three groups receiving different novel therapies. The study uses a design that allows adding or removing treatments based on their effectiveness and safety in this rare cancer. Participants will receive one of three treatments odronextamab given by intravenous infusion weekly and then less frequently over up to two years loncastuximab tesirine combined with modified R-ICE chemotherapy for up to three cycles or CAR T-cell therapy with details to be confirmed. These treatments are tested in parallel groups, and if a medicine appears ineffective, it may be stopped and replaced by another. The trial allows children to switch groups if their cancer does not respond. During the study, researchers will monitor participants through regular assessments including imaging and laboratory tests to evaluate cancer response and side effects. They will check treatment responses at specific times during treatment cycles and follow patients for at least two years after treatment to monitor long-term outcomes and safety. This includes tracking survival times, adverse events, and overall treatment effectiveness to provide important information about these new therapies.
Actively Recruiting
Healthy Volunteer
Researchers are studying chronic post-surgical pain CPSP in children aged 0 to 16 years who undergo common pediatric surgeries such as laparoscopic appendicectomy, scrotal exploration, orchidopexy, hypospadias repair, and circumcision. The study aims to understand how often CPSP occurs, its risk factors, and its effects on childrens physical, emotional, and social well-being. This observational study will collect information through questionnaires from before surgery up to one year after surgery. Participants will be grouped based on the type of surgery they receive elective surgeries including circumcision, hypospadias repair, orchidopexy, or laparoscopic appendicectomy, and emergency surgeries including laparoscopic appendicectomy or scrotal exploration. The study observes these groups without providing treatments, focusing on collecting data about their pain experiences and related factors over time. Children and their families will complete questionnaires at six different times before surgery, on Day 2 after surgery, at 3 to 4 weeks, 3 to 4 months, and 10 to 12 months post-surgery. These questionnaires assess pain levels, function, anxiety, and other factors. Researchers will track the prevalence of chronic post-surgical pain at 10 to 12 months and identify potential risk factors to help improve future care and guidelines for children at risk of long-term pain.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BW-41012 when given as a single subcutaneous injection to healthy adults aged 18 to 65 years. This randomized, double-blind, placebo-controlled study includes approximately 40 men and women divided into 5 cohorts to assess different dose levels of BW-41012. Participants will receive a single ascending dose of BW-41012 or placebo via subcutaneous injection. The study is structured into 5 cohorts, each with 8 participants receiving either the investigational drug or placebo. The trial employs a quadruple blinding and parallel assignment model to evaluate the investigational drugs effects compared to placebo. During the study, participants will undergo monitoring for up to 24 hours to assess primary endpoints, with additional evaluations extending up to 8 days and long-term safety follow-up up to 360 days. Assessments include laboratory tests, clinical evaluations, and safety monitoring to track drug effects and tolerability. The total participation duration can last up to nearly one year to ensure comprehensive evaluation of BW-41012.
Actively Recruiting
Researchers are investigating the drug OKN4395, alone and combined with pembrolizumab, in adults with advanced solid tumors. This Phase 1 study aims to assess the safety, tolerability, blood levels, and anti-tumor activity of OKN4395 both as a single treatment and alongside pembrolizumab. The study focuses on tumors with a COX2-associated immunosuppressive pathway and includes multiple cancer types such as sarcoma, non-small cell lung cancer, colorectal cancer, and gastric cancer. The study is divided into two main parts. Part 1a includes dose escalation of OKN4395 alone or with pembrolizumab every 21 days, increasing doses based on safety evaluations, and a substudy testing how food and stomach acid affect OKN4395 blood levels. Part 1b evaluates OKN4395 alone or combined with pembrolizumab in four cancer cohorts. Participants receive oral OKN4395 twice daily, with pembrolizumab given intravenously every three weeks where applicable. The substudy involves dosing under fasting, fed, and high stomach pH conditions using famotidine. Participants will be monitored through regular visits lasting up to 27 months for Part 1a and up to 12 months for Part 1b. Assessments include safety checks for side effects, blood tests for drug levels and lab abnormalities, ECGs, tumor measurements, and evaluation of treatment response and progression. The study tracks dose adjustments, adverse events, and survival outcomes to understand the drugs effects and tolerability in solid tumor patients.
Actively Recruiting
Researchers are studying bleximenib, a drug being evaluated for treating acute leukemia in this Phase 12 clinical trial. The study aims first to find the recommended dose of bleximenib that is safe and tolerable in adults and children with relapsed or refractory acute leukemia. The later phase will assess how well bleximenib works at that dose to fight leukemia. Participants in the early part of the study will receive increasing oral doses of bleximenib to identify safe levels. Then, more participants will take the recommended dose to confirm safety and learn about the drugs effects. In the Phase 2 part, participants will continue to take bleximenib orally at the recommended dose to evaluate its ability to induce remission and assess safety. During the study, participants will be monitored for side effects and response to treatment for up to nearly five years. Researchers will measure safety by tracking adverse events and dose-limiting toxicities in Phase 1, and remission rates in Phase 2. Blood tests, plasma drug levels, and assessments of leukemia response will be performed regularly. The study will also evaluate overall survival, event-free survival, and transfusion independence as important outcomes.
Actively Recruiting
Researchers are evaluating CT-202, a new humanized T cell engaging bispecific antibody targeting nectin-4, in people with nectin-4 positive recurrent, unresectable, or metastatic triple negative breast cancer TNBC, colorectal cancer CRC, or urothelial cancer UC that are resistant to standard treatments. This Phase 1a1b trial aims to assess the safety, tolerability, and early signs of effectiveness of CT-202. Results from this study including pharmacokinetics, pharmacodynamics, efficacy, and safety will help determine the recommended dose for future studies. The study includes two parts Phase 1a dose escalation uses a Bayesian Optimal Interval design with step-up dosing every two weeks across approximately six dose levels. Participants will continue treatment until disease progression, unacceptable side effects, withdrawal, or investigator decision. Phase 1b dose expansion will test CT-202 at two or more doses and dosing schedules across 4 to 6 groups of up to 15 participants each, focusing on the same cancer types. Data from Phase 1b will guide the recommended Phase 2 dose. Participants will undergo regular evaluations including safety monitoring and tumor assessments up to 24 months after the first dose. The main outcomes measured are dose limiting toxicities during Phase 1a and overall response rate during Phase 1b. The study includes participants aged 18 and older with measurable disease and adequate organ function. The treatment is given intravenously every two weeks, and participants are observed until disease progression or other study endpoints.
1-10 of 216
1